Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xianyu capsule is a traditional Chinese medicine (TCM) formulation used as an antiepileptic therapeutic agent. It is formulated by modifying and combining two classical TCM prescriptions: Qianzheng San (Symmetry-Restoring Powder) and Tianma Gouteng Yin (Gastrodia-Uncaria Decoction). The product contains 16 herbal ingredients, including Hedysarum Multijugum Maxim., Codonopsis Radix, Radix Salviae, Radix Bupleuri, Ziziphi Spinosae Semen, Polygala tenuifolia Willd., Rhizom Gastrodiae, Uncariae Ramulus Cumuncis, Curcumae Radix, Arisaema Cum Bile, Angelicae Sinensis Radix, Acoritataninowii Rhizoma, Bombyx Batryticatus, Massa Medicata Fermentata, licorice, Typhonii Rhizoma, and Glycyrrhiza uralensis Fisch. Clinical evidence suggests it modulates neuroinflammation and glycerophospholipid metabolism—potentially by regulating AKT1, insulin (INS), and interleukin-6 (IL-6)—and that its mechanism may involve effects on gut microbiota, lipid metabolism, and neuroinflammatory pathways. It is approved and used in China for the treatment of epilepsy, where it has demonstrated sedative, anticonvulsant, wind-extinguishing, and spasmolytic effects, with more than twenty years of clinical use[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xianyu capsule.